Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar

Table 2

Response to EVG/COBI/FTC/TAF treatment and tolerability.

Effect on HIV viral load	Number
Treatment naïve	29
Undetectable	20
Left the country	6
Failure	2
Changed to another regimen due to resistance	1
Treatment experienced	71
Undetectable virus at the start (55 patients)
Undetectable	50
Failure	3
Died	1
Left the country	1
Detectable virus at start (15 patients)
Undetectable	9
Failure	4
Changed due to resistance	1
No data	1
No data at start (1)
Failure	1
Effect on CD4
Base line before starting EVG/COBI/FTC/TAF
Mean	633
Range	(6–2286)
After starting EVG/COBI/FTC/TAF
Mean	734
Range	(6–2335)
Adverse drug effects
No side effects	87
Side effects	3
Headache	1
Abdominal pain	1
Elevated liver enzymes	1
Not evaluated	10
Effects on renal function
Normal function	95
Abnormal	5
Improved	2
No change	1
Worsened	2